Sanofi and AstraZeneca’s Beyfortus (Nirsevimab) is now approved by the National Pharmaceutical Regulatory Agency (NPRA) and ...
Zacks Investment Research on MSN
AstraZeneca (AZN) rises as market takes a dip: Key facts
In the latest close session, Astrazeneca (AZN) was up +1.93% at $91.56. The stock's change was more than the S&P 500's daily loss of 0.16%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq ...
Enhertu plus Perjeta is the first new first-line treatment for HER2-positive breast cancer in over a decade, approved by the ...
The FDA's approval is based on results from the Phase III DESTINY-Breast09 trial, in which the combo showed a median 40.7-month progression-free survival.
Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the first-line ...
After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a ...
(Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in ...
Here’s a closer look at the top pharmaceutical companies that have earned favorable rankings from Wolfe Research analysts. Johnson & Johnson takes the top spot with growth primarily driven by new ...
RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...
Matan Companies is proud to announce that its premier 44-acre life science and industrial campus fronting I-270 in ...
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback